Global Peptide Hormone Market & Pipeline Analysis
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Human body consists of myriad of chemicals required for signaling, providing nutrients, proper growth and development. Hormones are one such chemical present in the body that plays a very important role in maintaining homeostasis. They are secreted from endocrine glands which are also known as duct less gland because hormones are directly secreted into the blood stream. Moreover, diversity could be observed in their molecular structure, chemical nature, functionality, site of secretion and action. Among hormones, peptide hormones form an important category consisting of short amino acid chains of varying sizes. They are secreted in miniscule quantities but their effect is profound on target tissue which may be distant to the site of secretion. Despite this fact, they are indispensible in nature and investigators are trying to increase understanding about their action mechanism to come forth with suitable therapeutics.
Diseases due to deficiency of peptide hormone have been observed by investigators and cure for some of them has been marketed across the globe. Investigators have found more than 50 types of hormones in body belonging to different classes having characteristic biochemical and biophysical properties. In this way, they offer huge commercialization potential but all of them don’t have significant therapeutic benefits as compared to peptide hormones. They are customizable in nature due which they could be modulated according to the receptor molecules. As a result, their specificity increases several folds providing higher safety profile along with minimized side effects. Moreover, increased potency is among other benefits due to which lesser dosage is required for achieving higher therapeutic benefits. These favorable feature makes them a suitable candidate having significant therapeutic and commercialization potential in several disease categories.
Pharmaceutical companies have recognized the commercialization and therapeutic potential of peptide hormones for treating various diseases. As a result, they are investing more funds in research and development segment to develop novel therapeutics to fulfill high unmet medical necessities. Several peptide hormone drug development programs have been instigated by pharmaceutical companies which would help in generating significant revenues. Their administrations in several hormonal imbalances have shown proven safety and efficacy profiles leading to higher acceptance among patients. In past few years, new mechanisms have been deciphered by investigators that will offer more options to patients suffering from various peptide hormone disorders. It is expected that investigators would introduce innovative therapeutics in market due to increased funding in research and development segment.
Several years of knowledge has been gathered by investigators due to which market introduction of new peptide hormones is expected to take place in coming years. Progress has been made in improvement of peptide design and candidate molecule screening are undergoing through different phases of clinical trials. These innovative peptide hormones are expected to enter in global market in coming years for various disease categories. Due to significant therapeutic efficacy they are expected to compete effectively and erode profit of other therapeutics. Moreover, newer instruments are expected to be introduced for providing better control over quantity and quality of peptide hormones. Besides this their manufacturing capabilities are expected to increase several folds and introduction of superior technology will further allow the pharmaceutical manufacturers to achieve higher production at competitive pricing. With all these positive development, the future of peptide hormones seems to be optimistic.
“Peptide Hormones Market & Pipeline Insight 2015” Report Highlight:
Human body consists of myriad of chemicals required for signaling, providing nutrients, proper growth and development. Hormones are one such chemical present in the body that plays a very important role in maintaining homeostasis. They are secreted from endocrine glands which are also known as duct less gland because hormones are directly secreted into the blood stream. Moreover, diversity could be observed in their molecular structure, chemical nature, functionality, site of secretion and action. Among hormones, peptide hormones form an important category consisting of short amino acid chains of varying sizes. They are secreted in miniscule quantities but their effect is profound on target tissue which may be distant to the site of secretion. Despite this fact, they are indispensible in nature and investigators are trying to increase understanding about their action mechanism to come forth with suitable therapeutics.
Diseases due to deficiency of peptide hormone have been observed by investigators and cure for some of them has been marketed across the globe. Investigators have found more than 50 types of hormones in body belonging to different classes having characteristic biochemical and biophysical properties. In this way, they offer huge commercialization potential but all of them don’t have significant therapeutic benefits as compared to peptide hormones. They are customizable in nature due which they could be modulated according to the receptor molecules. As a result, their specificity increases several folds providing higher safety profile along with minimized side effects. Moreover, increased potency is among other benefits due to which lesser dosage is required for achieving higher therapeutic benefits. These favorable feature makes them a suitable candidate having significant therapeutic and commercialization potential in several disease categories.
Pharmaceutical companies have recognized the commercialization and therapeutic potential of peptide hormones for treating various diseases. As a result, they are investing more funds in research and development segment to develop novel therapeutics to fulfill high unmet medical necessities. Several peptide hormone drug development programs have been instigated by pharmaceutical companies which would help in generating significant revenues. Their administrations in several hormonal imbalances have shown proven safety and efficacy profiles leading to higher acceptance among patients. In past few years, new mechanisms have been deciphered by investigators that will offer more options to patients suffering from various peptide hormone disorders. It is expected that investigators would introduce innovative therapeutics in market due to increased funding in research and development segment.
Several years of knowledge has been gathered by investigators due to which market introduction of new peptide hormones is expected to take place in coming years. Progress has been made in improvement of peptide design and candidate molecule screening are undergoing through different phases of clinical trials. These innovative peptide hormones are expected to enter in global market in coming years for various disease categories. Due to significant therapeutic efficacy they are expected to compete effectively and erode profit of other therapeutics. Moreover, newer instruments are expected to be introduced for providing better control over quantity and quality of peptide hormones. Besides this their manufacturing capabilities are expected to increase several folds and introduction of superior technology will further allow the pharmaceutical manufacturers to achieve higher production at competitive pricing. With all these positive development, the future of peptide hormones seems to be optimistic.
“Peptide Hormones Market & Pipeline Insight 2015” Report Highlight:
- Global Peptide Hormone Market Overview
- Peptide Hormones Clinical Pipeline by Company, Indication & Phase
- Marketed Peptide Hormones by Company & Indication
- Peptide Hormones Clinical Pipeline: 47 Drugs
- Majority Peptide Hormone in Phase-II Trials: 15 Drugs
- Marketed Peptide Hormones: 24 Drugs
- Global Peptide Hormone Market Future Prospects
1. INTRODUCTION TO PEPTIDE HORMONES
2. MECHANISM OF PEPTIDE HORMONE THERAPY
3. GLOBAL PEPTIDE HORMONE MARKET OVERVIEW
3.1 Current Market Scenario
3.2 Peptide Hormones Pipeline Overview
4. GLOBAL PEPTIDE HORMONE MARKET DYNAMICS
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. GLOBAL PEPTIDE HORMONE MARKET FUTURE PROSPECTS
6. PEPTIDE HORMONES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
6.1 Unknown
6.2 Research
6.3 Preclinical
6.4 Phase-I
6.5 Phase-I/II
6.6 Phase-II
6.7 Phase-III
6.8 Preregistration
7. MARKETED PEPTIDE HORMONES BY COMPANY & INDICATION
8. DISCONTINUED & SUSPENDED PIPELINE BY COMPANY, INDICATION & PHASE
8.1 Discontinued
8.2 Market Withdrawal
8.3 No Development Reported
8.4 Suspended
9. COMPETITIVE LANDSCAPE
9.1 BioPartners
9.2 Boehringer Ingelheim
9.3 Eli Lily
9.4 Innovate Biopharmaceuticals
9.5 Merck
9.6 NovoNordisk
9.7 Par Pharmaceuticals
9.8 Pfizer
9.9 Roche
9.10 Sanofi
9.11 Tarix Pharmaceuticals
2. MECHANISM OF PEPTIDE HORMONE THERAPY
3. GLOBAL PEPTIDE HORMONE MARKET OVERVIEW
3.1 Current Market Scenario
3.2 Peptide Hormones Pipeline Overview
4. GLOBAL PEPTIDE HORMONE MARKET DYNAMICS
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. GLOBAL PEPTIDE HORMONE MARKET FUTURE PROSPECTS
6. PEPTIDE HORMONES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
6.1 Unknown
6.2 Research
6.3 Preclinical
6.4 Phase-I
6.5 Phase-I/II
6.6 Phase-II
6.7 Phase-III
6.8 Preregistration
7. MARKETED PEPTIDE HORMONES BY COMPANY & INDICATION
8. DISCONTINUED & SUSPENDED PIPELINE BY COMPANY, INDICATION & PHASE
8.1 Discontinued
8.2 Market Withdrawal
8.3 No Development Reported
8.4 Suspended
9. COMPETITIVE LANDSCAPE
9.1 BioPartners
9.2 Boehringer Ingelheim
9.3 Eli Lily
9.4 Innovate Biopharmaceuticals
9.5 Merck
9.6 NovoNordisk
9.7 Par Pharmaceuticals
9.8 Pfizer
9.9 Roche
9.10 Sanofi
9.11 Tarix Pharmaceuticals
LIST OF FIGURES
Figure 1-1: Properties of Peptide Hormone
Figure 1-2: Therapeutic Features of Peptide Hormones
Figure 1-3: Required Improvements for Peptide Hormones
Figure 2-1: Mechanism of Peptide Hormones
Figure 2-2: Mechanism of Insulin
Figure 2-3:Mechanism of Genotropin
Figure 2-4:Mechanism of Pitressin
Figure 2-5:Mechanism of Glucagon
Figure 3-1: Peptide Hormones Pipeline by Phase (%), 2015
Figure 3-2: Peptide Hormones Pipeline by Phase (Number), 2015
Figure 3-3: No Development Reported Peptide Hormones Pipeline by Phase (%), 2015
Figure 3-4: No Development Reported Peptide Hormones Pipeline by Phase (Number), 2015
Figure 3-5: Discontinued Peptide Hormones Pipeline by Phase (%), 2015
Figure 1-1: Properties of Peptide Hormone
Figure 1-2: Therapeutic Features of Peptide Hormones
Figure 1-3: Required Improvements for Peptide Hormones
Figure 2-1: Mechanism of Peptide Hormones
Figure 2-2: Mechanism of Insulin
Figure 2-3:Mechanism of Genotropin
Figure 2-4:Mechanism of Pitressin
Figure 2-5:Mechanism of Glucagon
Figure 3-1: Peptide Hormones Pipeline by Phase (%), 2015
Figure 3-2: Peptide Hormones Pipeline by Phase (Number), 2015
Figure 3-3: No Development Reported Peptide Hormones Pipeline by Phase (%), 2015
Figure 3-4: No Development Reported Peptide Hormones Pipeline by Phase (Number), 2015
Figure 3-5: Discontinued Peptide Hormones Pipeline by Phase (%), 2015
